Brought to you by 
Watson gets US rights to HRA Pharma's UPA contraceptive
06 Apr 2010
Executive Summary
Watson Pharmaceuticals (urology and women's health products) has licensed exclusive US rights to HRA Pharma's (endocrine and women's health therapeutics) ulipristal acetate (UPA) for use as an emergency contraceptive.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson gets US rights to HRA Pharma's UPA contraceptive
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice